Search hospitals > Texas > Houston
Baylor College of Medicine
Claim this profileHouston, Texas 77030
Global Leader in Lymphoma
Global Leader in Hypertension
Conducts research for Cancer
Conducts research for Arterial Tortuosity Syndrome
Conducts research for Dementia
1378 reported clinical trials
111 medical researchers
Summary
Baylor College of Medicine is a medical facility located in Houston, Texas. This center is recognized for care of Lymphoma, Hypertension, Cancer, Arterial Tortuosity Syndrome, Dementia and other specialties. Baylor College of Medicine is involved with conducting 1,378 clinical trials across 1,368 conditions. There are 111 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mohamed O. Othman, MD, and Carlos Ramos, MD.Area of expertise
1Lymphoma
Global LeaderCD19 positive
CD30 positive
2Hypertension
Global LeaderTop PIs
Jennifer Foster, MDBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center2 years of reported clinical research
Expert in Neuroblastoma
Expert in Cancer
34 reported clinical trials
53 drugs studied
Patricia Baxter, MDTexas Children's Hospital2 years of reported clinical research
Expert in Brain Tumor
Expert in Benign Glioma
32 reported clinical trials
40 drugs studied
Mohamed O. Othman, MDBaylor College of Medicine3 years of reported clinical research
Studies Gastrointestinal Cancer
Studies Digestive Cancer
17 reported clinical trials
27 drugs studied
Carlos Ramos, MDHouston Methodist Hospital2 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
12 reported clinical trials
16 drugs studied
Clinical Trials running at Baylor College of Medicine
Depression
Breast Cancer
Crohn's Disease
Epilepsy
Atrial Fibrillation
Hepatocellular Carcinoma
Pancreatic Cancer
Ovarian Cancer
Lymphoma
Liver Cancer
Deep Brain Stimulation
for Bipolar Disorder
This study is only enrolling at Baylor College of Medicine. The other research locations listed serve to support data analysis only. This research study is to investigate the use of technology called Deep Brain Stimulation (DBS) to potentially improve Treatment-Resistant Bipolar Depression (TRBD) symptoms in patients with severe cases. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in TRBD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for TRBD treatment. Its important for participants to understand that this is an investigational study where there could be a lack of effectiveness in improving TRBD symptoms. There may be no directly benefit from taking part in this study. This study is expected to last 20 months and involves 3 main steps. 1. Medical, psychiatric, and cognitive evaluations. 2. Implantation of a brain stimulation system. 3. Follow up after implantation of device, including programming, recording, and psychiatric testing. There are risks and benefits to this study which need to be considered when deciding to participate or not. Some of the risks are from surgery, the DBS device and programming, the tests involved, and potential loss of confidentiality, as well as other unknown risks. Some of the more serious risks involved in this study and the percentage that they occur: 1. Bleeding inside the Brain (1 to 2 percent). 2. Infection from the procedures (3 percent) 3. Seizure caused from the procedures (1.2 percent) However, the benefit of this study is that it may help relieve or decrease TRBD symptoms. This form of treatment has shown to reduce symptom severity in other cases. This could potentially improve quality of life and activities in daily routines. There is also a potential benefit to society in that the data the investigators will obtain from this study may help increase the understanding of the mechanisms underlying TRBD symptoms, as well as enhanced Deep Brain Stimulation techniques. Study participation is expected to last 20 months from the time the DBS device is activated and should include approximately 23 visits. These visits also include 8 separate, 24 hour stays at the Menninger NeuroBehvaioral Monitoring Unit (NBU). These 24-hour sessions will occur at multiple points throughout the study (1 week prior to surgery, the week preceding device activation, the week following activation, then after 2 weeks, 4 weeks, 6 months, 9 months, and 12 months). Participants will need to stay locally for the week of the NBU stay (typically Monday through Friday). Study visits will include clinician administered assessments and questionnaires, subject reported assessments, neuropsychological testing, and mobile behavioral assessments which will occur around 23 visits over the course of 20 months.
Recruiting1 award N/A5 criteria
Deep Brain Stimulation
for Depression
The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demonstrate device capability to selectively and predictably engage distinct brain networks 2. Delineate depression-relevant networks and demonstrate behavioral changes with network-targeted stimulation 3. Demonstrate that chronic DBS using steered, individualized targeting is feasible and safe for reducing depressive symptoms
Recruiting1 award N/A13 criteria
Brain Stimulation
for Depression
Depression is one of the most common disorders of mental health, affecting 7-8% of the population and causing tremendous disability to afflicted individuals and economic burden to society. In order to optimize existing treatments and develop improved ones, the investigators need a deeper understanding of the mechanistic basis of this complex disorder. Previous work in this area has made important progress but has two main limitations. (1) Most studies have used non-invasive and therefore imprecise measures of brain activity. (2) Black box modeling used to link neural activity to behavior remain difficult to interpret, and although sometimes successful in describing activity within certain contexts, may not generalize to new situations, provide mechanistic insight, or efficiently guide therapeutic interventions. To overcome these challenges, the investigators combine precise intracranial neural recordings in humans with a suite of new eXplainable Artificial Intelligence (XAI) approaches. The investigators have assembled a team of experimentalists and computational experts with combined experience sufficient for this task. Our unique dataset comprises two groups of subjects: the Epilepsy Cohort consists of patients with refractory epilepsy undergoing intracranial seizure monitoring, and the Depression Cohort consists of subjects in an NIH/BRAIN-funded research trial of deep brain stimulation for treatment-resistant depression (TRD). As a whole, this dataset provides precise, spatiotemporally resolved human intracranial recording and stimulation data across a wide dynamic range of depression severity. Our Aims apply a progressive approach to modeling and manipulating brain-behavior relationships. Aim 1 seeks to identify features of neural activity associated with mood states. Beginning with current state-of-the-art AI models and then uses a "ladder" approach to bridge to models of increasing expressiveness while imposing mechanistically explainable structure. Whereas Aim 1 focuses on self-reported mood level as the behavioral index of interest, Aim 2 uses an alternative approach of focusing on measurable neurobiological features inspired by the Research Domain Criteria (RDoC). These features, such as reward sensitivity, loss aversion, executive attention, etc. are extracted from behavioral task performance using a novel "inverse rational control" XAI approach. Relating these measures to neural activity patterns provides additional mechanistic and normative understanding of the neurobiology of depression. Aim 3 uses recurrent neural networks to model the consequences of richly varied patterns of multi-site intracranial stimulation on neural activity. Then employing an innovative "inception loop" XAI approach to derive stimulation strategies for open- and closed-loop control that can drive the neural system towards a desired, healthier state. If successful, this project would enhance our understanding of the pathophysiology of depression and improve neuromodulatory treatment strategies. This can also be applied to a host of other neurological and psychiatric disorders, taking an important step towards XAI-guided precision neuroscience.
Recruiting1 award N/A
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Baylor College of Medicine?
Baylor College of Medicine is a medical facility located in Houston, Texas. This center is recognized for care of Lymphoma, Hypertension, Cancer, Arterial Tortuosity Syndrome, Dementia and other specialties. Baylor College of Medicine is involved with conducting 1,378 clinical trials across 1,368 conditions. There are 111 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mohamed O. Othman, MD, and Carlos Ramos, MD.
Where is Baylor College of Medicine located?
Baylor College of Medicine is located in the Texas Medical Center at 6651 Main St, Houston, TX, offering easy access via major freeways and thoroughfares.
Who should I call to ask about financial aid or insurance network?
For general inquiries at Baylor College of Medicine, please call (713) 798-4951. For financial assistance or billing concerns, contact the Baylor Scott & White Health Financial Assistance Program at 1-800-725-0024 (North Texas) or 1-800-994-0371 (Central Texas). The Baylor College of Medicine Billing Office is available at (713) 798-1900 for billing questions.
What insurance does Baylor College of Medicine accept?
The Baylor College of Medicine accepts a variety of insurance plans, including HMO, PPO, and POS managed care programs. Baylor Scott & White Health facilities accept Traditional Medicaid, Traditional Medicare, and any Medicare Supplement/Medigap plan, along with being contracted providers for insurance companies like Aetna, Blue Cross Blue Shield, Cigna, Humana, and more. Always verify coverage with the hospital or health plan before scheduling a visit or procedure.
What awards or recognition has Baylor College of Medicine received?
Baylor College of Medicine has been awarded a $14.85 million grant for neurological research and $24 million for cancer research and prevention. Additionally, they provide collaborative pilot grants in partnership with the University of Houston and have received awards funded by the DeBakey Medical Foundation.